These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19549771

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB, Zimmer MA, Sathiaseelan V, Benson AB, Mittal RR, Dutta S, Rosen ST, Spies SM, Mettler JM, Groch MW.
    Cancer; 1996 Nov 01; 78(9):1861-70. PubMed ID: 8909304
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ.
    J Clin Oncol; 2003 Dec 01; 21(23):4428-38. PubMed ID: 14645433
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
    Buchegger F, Allal AS, Roth A, Papazyan JP, Dupertuis Y, Mirimanoff RO, Gillet M, Pelegrin A, Mach JP, Slosman DO.
    Anticancer Res; 2000 Dec 01; 20(3B):1889-96. PubMed ID: 10928122
    [Abstract] [Full Text] [Related]

  • 11. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.
    Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, Xing JL, Bian HJ, Jiang JL, Wang XH, Shang P, Qian AR, Zhang SH, Li L, Li Y, Feng Q, Yu XL, Feng Y, Yang XM, Tian R, Wu ZB, Leng N, Mo TS, Kuang AR, Tan TZ, Li YC, Liang DR, Lu WS, Miao J, Xu GH, Zhang ZH, Nan KJ, Han J, Liu QG, Zhang HX, Zhu P.
    Int J Radiat Oncol Biol Phys; 2006 Jun 01; 65(2):435-44. PubMed ID: 16690431
    [Abstract] [Full Text] [Related]

  • 12. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J.
    J Nucl Med; 2006 Feb 01; 47(2):247-55. PubMed ID: 16455630
    [Abstract] [Full Text] [Related]

  • 13. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.
    Clin Cancer Res; 2003 May 01; 9(5):1639-47. PubMed ID: 12738716
    [Abstract] [Full Text] [Related]

  • 14. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Mar 01; 38(3):409-18. PubMed ID: 9074529
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of combretastatin a-4 phosphate with carboplatin.
    Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ.
    Clin Cancer Res; 2005 Feb 15; 11(4):1527-33. PubMed ID: 15746056
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 15; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 17. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
    Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, Goldenberg DM.
    J Nucl Med; 1996 Sep 15; 37(9):1504-10. PubMed ID: 8790202
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM.
    Clin Cancer Res; 2005 Jul 01; 11(13):4818-26. PubMed ID: 16000579
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM.
    Clin Cancer Res; 2000 Sep 01; 6(9):3621-8. PubMed ID: 10999754
    [Abstract] [Full Text] [Related]

  • 20. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, Paleologos N, Fredericks RK, Schold SC, Bigner DD.
    Clin Cancer Res; 1996 Jun 01; 2(6):963-72. PubMed ID: 9816257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.